- Home
- NYC vs LGVN Comparison
NYC vs LGVN Comparison
Compare NYC & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NYC | LGVN |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.9M | 21.4M |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NYC | LGVN |
|---|---|---|
| Price | $5.66 | $2.37 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $61.25 |
| AVG Volume (30 Days) | 15.4K | ★ 145.7K |
| Earning Date | 11-18-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 85.28 | 50.76 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $709,000.00 |
| Revenue This Year | $35.25 | $46.15 |
| Revenue Next Year | N/A | $396.46 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.52 | $0.48 |
| 52 Week High | $13.97 | $7.60 |
Technical Indicators
Market Signals| Indicator | NYC | LGVN |
|---|---|---|
| Relative Strength Index (RSI) | 32.67 | 38.12 |
| Support Level | N/A | $2.30 |
| Resistance Level | $8.89 | $7.30 |
| Average True Range (ATR) | 0.40 | 0.25 |
| MACD | 0.03 | -0.20 |
| Stochastic Oscillator | 10.53 | 13.42 |
Price Performance
Historical ComparisonAbout NYC American Strategic Investment Co.
American Strategic Investment Co is an externally managed company that currently owns a portfolio of commercial real estate located within the five boroughs of New York City, majorly Manhattan. The Company's real estate assets consist of office properties and certain real estate assets that accompany office properties, including retail spaces and amenities.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.